PDF(Pubmed)
Abstract：
The COVID-19 pandemic highlighted the importance of effective vaccination strategies in controlling the spread of infectious diseases. SARS-CoV-2 vaccine has demonstrated high efficacy in preventing COVID-19 infection in the general population. However, the efficacy of this vaccine in patients with predominantly antibody deficiencies, such as common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA), should be closely monitored. CVID and XLA are rare genetic disorders that impair the immune system\'s ability to produce antibodies, which are crucial for fighting infections. Patients with these disorders have a higher risk of severe disease and mortality from COVID-19 due to their compromised immune systems. In this study, we evaluated the humoral and cellular immune responses after four doses of mRNA-1273 and one BNT162b2 bivalent vaccine in a cohort of patients with CVID and XLA. The response in this population was lower than in the control group. However, the administration of the third dose improved the number of patients with seroconversion and the intensity of the humoral response, as well as the number of patients with a positive cellular response. Finally, the administration of the fourth and fifth doses improves the antibody titer and neutralization against wild type variant, but not against the prevalent XBB1.5 variant.
摘要：
COVID-19大流行强调了有效疫苗接种策略在控制传染病传播方面的重要性。SARS-CoV-2疫苗在预防普通人群中的COVID-19感染方面表现出很高的效力。然而,这种疫苗在主要抗体缺乏的患者中的功效，如普通可变免疫缺陷(CVID)和X连锁无球蛋白血症(XLA)，应该密切监测。CVID和XLA是罕见的遗传性疾病，会损害免疫系统产生抗体的能力，这对对抗感染至关重要。患有这些疾病的患者由于免疫系统受损，患COVID-19严重疾病和死亡的风险更高。在这项研究中,我们在一组CVID和XLA患者中评估了4剂mRNA-1273和1种BNT162b2二价疫苗后的体液和细胞免疫应答.该人群的反应低于对照组。然而,第三剂的给药改善了血清转换患者的数量和体液反应的强度，以及细胞反应阳性的患者人数。最后,第四和第五剂量的施用提高了抗体滴度和针对野生型变体的中和,但不是针对流行的XBB1.5变体。
